Kedrion joins Rhesus Solution Initiative (RSI) symposium in Lagos
Nigeria to advocate for Rh Disease universal eradication
Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017
The prize is awarded to the companies that made the best use of the capital markets
Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme
Goal is to improve access to replacement therapies for coagulation disorders in Europe
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)
The agreement aims to improve patient access to coagulation disorders treatments in Europe
New company AO Kirov Plasma established in Russia
It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard
Kedrion Biopharma strengthens its presence in Russia
Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program
Kedrion Biopharma consolidates presence on Russian market
Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant
SIPPET study results published in the “New England Journal of Medicine”
This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world